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Appraisal Critically Appraised Papers
Exercise therapy alone and exercise therapy after 
corticosteroid injection are equally effective after 12 weeks 
for moderate to severe shoulder pain
Synopsis
Summary of: Crawshaw DP et al (2010) Exercise therapy 
after corticosteroid injection for moderate to severe 
shoulder pain: large pragmatic randomised. BMJ 340: 
c3037 doi:10.1136/bmj.c3037 [Prepared by Margreth Grotle 
and Kåre Birger Hagen, CAP Editors.]
Question: Does subacromial corticosteroid injection 
combined with timely exercise and manual therapy (injection 
plus exercise) or exercise and manual therapy alone (exercise 
only) improve shoulder pain and disability in patients with 
subacromial impingement syndrome? Design: A pragmatic 
randomised, controlled trial with block randomisation 
and group allocation by using an independent telephone 
randomisation service. Setting: Primary care based 
musculoskeletal service in UK. Participants: Men and 
women 40 years or older with unilateral shoulder pain with 
moderate or severe pain intensity on a 3-point scale, and 
with a non-capsular pattern of restriction. Key exclusion 
criteria were evidence of other pathological conditions in 
the shoulder and neck. Randomisation of 232 participants 
allocated 115 to the ‘injection plus exercise’ group and 117 
to the ‘exercise only’ group. Interventions: Both groups 
received standard advice to avoid activities that caused or 
provoked pain. The physiotherapy program started one 
week after the subacromial injection or immediately in the 
exercise only arm. The training sessions were individually 
adapted and comprised a selection of six mobilisation 
techniques and 23 progressive exercises. The patients 
attended as many sessions as deemed necessary by the 
treating physiotherapist. In addition, the intervention group 
received one injection of 20 mg triamcinolone acetonide 
mixed with 4.5 ml 1% lidocaine (lignocaine) at the mid-
point of the acromion, which could be repeated after six 
weeks in patients with ongoing pain. Outcome measures: 
The primary outcome was the difference in improvement 
in the total shoulder pain and disability index (SPADI) at 
12 weeks. The secondary outcome measure was global 
assessment of change on a 5-point scale. Results: 193 of 
participants completed the study, 96 in the ‘injection plus 
exercise’ group and 97 to the ‘exercise only’ group. At Week 
12 there was no signiﬁcant difference between the groups 
in change in SPADI scores: the mean difference between 
change in groups was 3.3 (95% CI −0.8 to 7.3). Improvement 
was signiﬁcantly greater in the injection plus exercise group 
at Week 1 (6.6, 95% CI 4.3 to 8.8) and Week 6 (7.4, 95% 
CI 4.3 to 10.4) for the SPADI, with no differences at Week 
24 (−2.3, 95% CI −6.8 to 2.3). For the secondary outcome 
a similar pattern was seen, with no signiﬁcant differences 
at Weeks 12 and 24. For the secondary outcome a similar 
pattern was seen, with no signiﬁcant differences at Weeks 
12 and 24. Conclusion: In the treatment of patients with 
subacromial impingement syndrome, injection plus exercise 
and exercise only are similarly effective at 12 weeks.
Commentary
This trial investigated whether reduced pain from a 
corticosteroid injection and lidocaine before starting an 
exercise therapy program would result in better outcome 
than exercise therapy only. Hence one cannot know whether 
it was the lidocaine or the steroid injection that gave pain 
relief. With this in mind, the title is somewhat misleading.
The study is well conducted. The authors have performed 
Rasch transformation of the main outcome instrument, 
SPADI. As far as we know this has previously been applied 
only for the SPADI disability subscale (Cook et al 2001).
The applied interventions are pertinent for this patient group 
(Green et al 2006). The outcomes measures (the SPADI and 
global assessment of change) were related only to shoulder 
pain and disability, and not to health related quality of life 
(HRQL) or work status. These are also important outcomes 
to consider with respect to both short and long term follow-
up studies.
The treatment program was individualised, but we do not 
know the criteria for selecting the physiotherapists or how 
experienced the physiotherapists were in treating this patient 
group. This may have inﬂuenced the number of treatment 
sessions which was left to the physiotherapist to decide.
The authors compare their long term results with Hay et 
al (2003), but their short term results differ. This is not 
discussed. With this exception, the short term results were 
in accordance with other studies, and show that injections 
could be of short term beneﬁt to patients with moderate to 
severe shoulder pain (Kuhn et al 2009). Long term follow-
up was as reported in other studies.
Future studies could investigate exercise therapy after 
lidocaine injection only (without a steroid injection) for 
patients with moderate to severe shoulder pain, and in 
addition include work status and HRQL as outcomes.
Kaia Engebretsen and Helene L Soberg
Oslo University Hospital, Ullevaal
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